

## CURRICULUM VITAE

<b>Name</b>	Youngwoo Jeon	<b>Country</b>	Republic of Korea
<b>Current Position</b>	<ul style="list-style-type: none"> <li>● Subdivision head, Division of hematology, Department of Internal medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea (CUK)</li> <li>● Manager of Lymphoma and Cell-therapy Research Center, Yeouido St. Mary's Hospital, The Catholic University of Korea (CUK)</li> <li>● Institute for Translational Research and Molecular Imaging (iTRMI), Catholic Medical Center</li> <li>● Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul St. Mary's Hospital</li> </ul>		

### **Educational Background**

#### **Education**

Feb. 2002 : Graduated from College of Medicine, SoonChunHyang Univ. Korea

#### **Degree**

Mar. 2002 : Medical Doctor, College of Medicine, SoonChunHyang Univ. Korea

Mar. 2013 : Master of internal medicine, College of Medicine, SoonChunHyang Univ. Korea

Feb. 2019: Doctor of Philosophy in Medical Science, Internal Medicine, Catholic University of Korea (CUK), Seoul.

### **Professional Experiences**

Mar. 2013 ~ Feb. 2015: Fellowship, Seoul St. Mary's Hospital, CUK

Mar. 2015 ~ Mar. 2019: Clinical Assistant Professor, Seoul St. Mary's Hospital, CUK

April. 2019 ~ Feb.2023 : Assistant Professor, Yeouido St. Mary's Hospital, CUK

Mar. 2023 ~ present : Associate Professor, Yeouido St. Mary's Hospital, CUK

Division head of hematology of Yeouido St. Mary's Hospital, CUK

Manager of Lymphoma and Cell-therapy research of Yeouido St. Mary's Hospital, CUK

Subdivision head of Catholic Institute of Cell Therapy

### **Professional Organizations**

Academic Committee Member of the Korean Society of Hematology, Since 2022

CAR-T Committee Member of the Korean Society of Hematology, Since 2023

Member of American Society of Hematology, since 2018

Member of European Hematology Association since 2020

The Korean Society of Hematology, Cell therapy association, since 2024

The Korean Society of Internal Medicine, since 2013

The Korean Society of Hematology, since 2013

The Korean Cancer Study Group, since 2013

The Korean Society of Experimental Hematology, since 2014



The Korean Society of Blood and Marrow Transplantation, since 2013

### Main Scientific Publications

#### (A Selection of Papers Published within the Last Seven Years)

1. Jeon YW, Min GJ, and Cho SG. Evaluation of the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT. *Blood* (2023) 142 (Supplement 1): 2227.(Abstract)
2. Jeon YW, Jeong YR, Yu MS, Kim RE, and Lim JY. Efficacy of Protac-Based EZH2 Degradator MS1943 in Lymphoid Malignancies: A Comprehensive Study on the Combined Effects of MS1943 and Ibrutinib, *Front Oncol.* 2023; 13: 1252658.
3. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG. Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients, *Cytotherapy* (2023); 25(8).
4. Jeon YW, Jeong YR, Yu MS, Kim RE, and Lim JY. Dual Targeting of EZH2 Degradation and EGFR/HER2 Inhibition for Enhanced Efficacy against Burkitt's Lymphoma, *Cancers* (2023); 15(18):4472
5. Jeon YW, Duk-Hwan Yang, Suk-Joong Oh, Jin-Hee Park, Jung-Ah Kim, Sung-Young Kim, Chul-Won Choi, Won-Sik Lee, In-Ho Kim, Yeung-Chul Mun, Gi June Min, Ki-Seong Eom, Seok-Goo Cho. Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study. *Frontiers in Oncology.* 2023 Mar 28;13:998014.
6. Jeon YW, Lim JY, Im KI, Kim NY, Cho SG. BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B-cell homeostasis, *Frontiers in Immunology* 2022 13 :995149.
7. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG. Prognostic Impact of Interim Positron Emission Tomography in Mantle Cell Lymphoma Patients Treated with Frontline R-CHOP, *British Journal of Haematology* 2020
8. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience, *Cancer Medicine* 2019
9. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma, *Annals of Hematology* (2019)

10. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non- Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation, Clinical Lymphoma, Myeloma & Leukemia (2019)
11. Jeon YW, Lim JY, Im KI, Nam YS, Song YJ, Cho SG. (2018) Enhancement of Graft-versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1-Regulatory T Cells in Bone Marrow Transplant Model. Stem Cells Dev. doi.org/10.1089/scd.2018.0113.
12. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG, Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome. Clinical Lymphoma, Myeloma & Leukemia (2017)
13. Jeon YW, Kim N, Nam YS, Lim JY, Im KI, Lee ES, Cho SG. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells. Cytokine. 2016;78:22–6.
14. Lim JY, Jeon YW, Im KI, Lee ES, Kim N, Nam YS, Cho SG: Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory t cells in collagen-induced arthritis. Scientific reports 2016;6:26851.
15. Jeon YW, Ahn TS, Jeong DJ, Son MW, Jung HI, Park SY, Kim HJ, Bae SB, Kim HJ, Lee MS, Baek MJ. The BRAF mutation is associated with the prognosis in colorectal cancer. J. Cancer Res. Clin. Oncol. 2014;140(11):1863–71.
16. Jeon YW, Yang HJ, Choi BO, Jung SE, Park KS, O JH, Yang SW, Cho SG. Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma. EClinicalMedicine 4–5 (2018) 32–42.
17. Jeon YW, Kwak DH, Park SS, Yoon JH, Lee SE, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, Min WS, Cho SG. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):595-603. doi: 10.1016/j.clml.2017.06.027.